|NCS: Researchers at Purdue University have developed a high-throughput platform for identifying drug candidates. The drug discovery process is expensive and time-consuming, requiring years to develop a commercial drug. This can be attributed to the manual, fragmented steps in the process. The Purdue researchers developed an automated sample-handling system that synthesizes and analyzes libraries of chemical compounds and then runs biological assays on the compounds. The system can screen 6,144 reactions in one hour at ultra-small quantities ("make-to-measure"), allowing the analysis of many reaction conditions to select the optimal conditions. The system conducts analysis via desorption electrospray ionization mass spectrometry (DESI-MS). The DESI-MS system is used to both identify compounds and analyze the results of enzymatic/receptor assays for cytotoxicity and bioactivity. For high-interest candidate compounds, Raman spectroscopy can be conducted and the results compared to predicted spectra. The researchers identified new non-addictive highly-potent opioids and new oximes (chemical warfare agent antidotes) as potential classes of compounds for analysis with this system.
Technology Validation: The researchers' system can screen 6,144 reactions in one hour and can screen cytotoxicity and bioactivity at a rate of 384 samples per hour.
-Identifies ideal reaction conditions
-Identifying and evaluating non-addictive pain medication and high-potency overdose reversal treatment
-Creating databases of synthetic opioids not yet introduced onto the streets
Mar 18, 2021
May 20, 2020
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906
Phone: (765) 588-3475
Fax: (765) 463-3486